Impact News +++ BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study (GlobeNewswire EN) +++ BRIDGEBIO Aktie +4,40%

IMPLANTICA Aktie

>IMPLANTICA Aktienkurs

5.05 EUR -3.6% (Tradegate)

Ask: 5.17 EUR / 390 Stück

Bid: 5.1 EUR / 400 Stück

Tagesumsatz: 50 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IMPLANTICA Aktie über LYNX handeln

Intraday

1 Jahr

>IMPLANTICA Performance

1 Woche: +0,4%

1 Monat: -16,7%

3 Monate: -13,2%

6 Monate: +101,9%

1 Jahr: +41,4%

laufendes Jahr: +73,8%

>IMPLANTICA Aktie

Name:

IMPLANTICA AG SDR./1

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0014855029 / A2QCUH

Symbol/ Ticker:

8IM1 (Frankfurt)

Kürzel:

FRA:8IM1, ETR:8IM1, 8IM1:GR

Index:

Webseite:

https://www.implantica.co..

Profil:

Implantica AG SDR represents shares of Implantica ..
>Volltext..

Marktkapitalisierung:

304.22 Mio. EUR

Unternehmenswert:

279.47 Mio. EUR

Umsatz:

2 Mio. EUR

EBITDA:

-16.58 Mio. EUR

Nettogewinn:

-22.25 Mio. EUR

Gewinn je Aktie:

-0.32 EUR

Schulden:

Liquide Mittel:

22.19 Mio. EUR

Operativer Cashflow:

-18.02 Mio. EUR

Bargeldquote:

10.72

Umsatzwachstum:

1.55%

Gewinnwachstum:

10.16%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IMPLANTICA

Letzte Datenerhebung:

27.10.25

>IMPLANTICA Kennzahlen

Aktien/ Unternehmen:

Aktien: 58.19 Mio. St.

Frei handelbar: -

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 27.78%

Bewertung:

KGV: -

KGV lG: -

KUV: 175.67

KBV: 3.13

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -76.21%

Gewinnmarge: -1110.93%

Operative Marge: -997.78%

Managementeffizenz:

Gesamtkaprendite: -20.65%

Eigenkaprendite: -20.85%

>IMPLANTICA Peer Group

Es sind 149 Aktien bekannt.

>IMPLANTICA Chart & Kurs - Tradegate

>IMPLANTICA News

27.10.25 - 09:48	Implantica presents the third quarter 2025 on October 31 at 15:00 CET (PR Newswire)
	VADUZ, Liechtenstein, Oct. 27, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2025 at 15:00 CET on October 31. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day. The presentation will be in......

13.10.25 - 11:03	Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application (PR Newswire)
	VADUZ, Liechtenstein, Oct. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers,......

06.10.25 - 08:24	Implantica Successfully Completes MDSAP Recertification Audit (PR Newswire)
	VADUZ, Liechtenstein, Oct. 6, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers,......

25.09.25 - 08:15	Implantica steps up to close the treatment gap with RefluxStop® as main device competitor exits Europe and the UK (PR Newswire)
	VADUZ, Liechtenstein, Sept. 25, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces......

24.09.25 - 08:21	Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3 (PR Newswire)
	VADUZ, Liechtenstein, Sept. 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces......

17.09.25 - 08:18	Implantica′s RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval (PR Newswire)
	VADUZ, Liechtenstein, Sept. 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers,......

10.09.25 - 21:01

Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration (Cision)

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces that on 09 September 2025 the company executed a directed share issue without payment to service parts of the equity incentive program for key employees. A total of 114'931 new SDRS have been created representing a 0.2 % increase in the total number of SDRs. The total number of outstanding SDRs has increased to 58'326'468 post issuance from 58'211'537 pre issuance. The Annual General Meeting held on 10 May 2022 authorized the Board of Directors to execute a Long-Term...

10.09.25 - 08:18	Implantica ramps-up production with 10,000 RefluxStop® units in preparation for U.S. launch, pending FDA PMA approval (PR Newswire)
	VADUZ, Liechtenstein, Sept. 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers,......

14.08.25 - 08:33	Implantica publishes Interim Report January - June 2025 (Q2) (PR Newswire)
	VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA)......

14.08.25 - 08:01

Implantica publishes Interim Report January – June 2025 (Q2) (Cision)

Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 · FDA PMA Submission Completed – Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term · Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) · Additional...

13.08.25 - 08:09	Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval (PR Newswire)
	VADUZ, Liechtenstein, Aug. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers,......

07.08.25 - 13:24	Implantica presents the second quarter 2025 on August 14 at 15:00 CEST (PR Newswire)
	VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the second quarter 2025 at 15:00 CEST on August 14. The interim report for the second quarter will be published at 8:00 a.m. CEST on the same day. The presentation will be in......

07.08.25 - 08:18	Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop® clinical study (PR Newswire)
	VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed publication of the remarkable 5-year outcomes from its CE mark clinical study of RefluxStop®, a......

01.07.25 - 08:21	Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success (PR Newswire)
	VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop®, a treatment field with 1 billion sufferers, announces the publication of RefluxStop's extraordinary 5-year clinical......

24.06.25 - 08:18	Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval (PR Newswire)
	VADUZ, Liechtenstein, June 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces......

17.06.25 - 08:21	Implantica announces successful UK RefluxStop™ Users Meeting addressing growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals (PR Newswire)
	VADUZ, Liechtenstein, June 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of treatment for acid reflux with its unique device RefluxStop™, a treatment field with 1 billion sufferers, announces the successful first UK National Users Meeting bringing......

12.06.25 - 08:36	Implantica announces new real-world Swiss study on 99 RefluxStop™ patients comparing small and large hiatal hernia, confirming equally excellent long-term results (PR Newswire)
	VADUZ, Liechtenstein, June 12, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces......

04.06.25 - 08:15	Implantica announces that UK NICE has published positive recommendations for the RefluxStop™ procedure in the NHS public hospitals (PR Newswire)
	VADUZ, Liechtenstein, June 4, 2025 /PRNewswire/ -- Implantica AG (publ.), providing the unique device RefluxStop™ for the treatment of acid reflux, announces that the world-renowned National Institute for Healthcare Excellence (NICE) payer advisory agency for NHS public hospitals in the......

27.05.25 - 08:21	Implantica′s RefluxStop™ stimulates intensive dialogue at DDW, the world′s largest Digestive Disease conference, held in the U.S. (PR Newswire)
	VADUZ, Liechtenstein, May 27, 2025 /PRNewswire/ -- Implantica AG (publ.) reports successful pre-launch activities in the U.S., pending FDA approval, with European real-world clinical evidence generating much interest from U.S. surgeons. Several presentations on RefuxStop™ were held at......

15.05.25 - 20:54	Bulletin from the Annual General Meeting of Implantica AG (PR Newswire)
	VADUZ, Liechtenstein, May 15, 2025 /PRNewswire/ -- Today, May 15, 2025, the annual general meeting (the "AGM") of Implantica AG (publ) was held in Ruggell, Liechtenstein. The general meeting resolved to adopt all of the board of directors' resolution proposals. A summary of the......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die meisten freien Schriftsteller sind nur Nebenerwerbsschriftsteller. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram